دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes
Paul Lacaze, P HD, a Andrew Bakshi, P HD, a Moeen Riaz, P HD, a Galina Polekhina, PHD, a Alice Owen, PHD, a Harpreet S. Bhatia, MD,b Pradeep Natarajan, MD,c,d,e Rory Wolfe, PH D, a Lawrence Beilin, MD,f Stephen J. Nicholls, MD, a,g Gerald F. Watts, MD, h,i John J. McNeil, MD, PH D, a Andrew M. Tonkin, MD,a, * Sotirios Tsimikas, MD
doi : 10.1016/j.jacc.2022.07.027
Volume 80, Issue 14, 4 October 2022, Pages 1287-1298
The role of aspirin in reducing lipoprotein(a)-mediated atherothrombotic events in primary prevention is not established.
Lp(a): Are Antithrombotic Therapies the Key to Event Reduction?∗
Ana Devesa, MD, PH D, a,b,c Borja Ibanez, MD, PHD, a,d,e Valentin Fuster, MD, PHD
doi : 10.1016/j.jacc.2022.08.722
Volume 80, Issue 14, 4 October 2022, Pages 1299-1301
Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction
Jonathan W. Cunningham, MD, MPH, a Muthiah Vaduganathan, MD, MPH,a Brian L. Claggett, PHD, a Ian J. Kulac, MS, a Akshay S. Desai, MD, MPH,a Pardeep S. Jhund, MBCHB, PHD, b Rudolf A. de Boer, MD,c David DeMets, PH D, d Adrian F. Hernandez, MD, e Silvio E. Inzucchi, MD,f Mikhail N. Kosiborod, MD,g Carolyn S.P. Lam,h Felipe Martinez, MD,i Sanjiv J. Shah, MD,j Martina M. McGrath, MBBC H,a Eileen O’Meara, MD, k Ulrica Wilderäng, PHD, l Daniel Lindholm, MD, PHD, l Magnus Petersson, MD,l Anna Maria Langkilde, MD, PHD, l John J.V. McMurray, MD, b Scott D. Solomon, MD
doi : 10.1016/j.jacc.2022.07.021
Volume 80, Issue 14, 4 October 2022, Pages 1302-1310
Patients recently hospitalized for heart failure (HF) are at high risk for rehospitalization and death.
SGLT2 Inhibitors Should Be Considered for All Patients With Heart Failure
Tariq Ahmad, MD, MPH, Nihar R. Desai, MD, MPH, Eric J. Velazquez, MD
doi : 10.1016/j.jacc.2022.08.005
Volume 80, Issue 14, 4 October 2022, Pages 1311-1313
Hemodynamic and Clinical Performance of Hearts Donated After Circulatory Death
David A. D’Alessandro, MD, a, * Stanley B. Wolfe, MD, MPH, a, * Asishana A. Osho, MD, MPH, a Kamila Drezek, BS, a Monica N. Prario, BS, a S. Alireza Rabi, MD, P HD, a Eriberto Michel, MD, a Lana Tsao, MD, b Erin Coglianese, MD, b Meaghan Doucette, NP, b Daniel A. Zlotoff, MD, b Christopher Newton-Cheh, MD, MPH,b,c Sunu S. Thomas, MD,b Van-Khue Ton, MD, PHD, b Nilay Sutaria, MD, b Mark W. Schoenike, BS, b Anastasia M. Christ, BA, b Dane C. Paneitz, MD, a Mauricio Villavicencio, MD, d Joren C. Madsen, MD, DP HIL ,a,e Richard Pierson, MD, a Gregory D. Lewis, MDb
doi : 10.1016/j.jacc.2022.07.024
Volume 80, Issue 14, 4 October 2022, Pages 1314-1326
Donor organ demand continues to outpace supply in heart transplantation. Utilization of donation after circulatory death (DCD) hearts could significantly increase heart donor availability for patients with advanced heart failure.
Donation of Hearts After Circulatory Death: A Life Saver
Ulrich P. Jorde, MD
doi : 10.1016/j.jacc.2022.07.025
Volume 80, Issue 14, 4 October 2022, Pages 1327-1329
Population-Based Recalibration of the Framingham Risk Score and Pooled Cohort Equations
Maneesh Sud, MD, a,b,c,d Atul Sivaswamy, MS C,c Anna Chu, MHS C ,c,d Peter C. Austin, PH D, b,c Todd J. Anderson, MD, e,f David M.J. Naimark, MD, MSC ,b,c,d Michael E. Farkouh, MD, MS C,d,g,h Douglas S. Lee, MD, PHD, d,g,h Idan Roifman, MD, MS C,a,b,c,d George Thanassoulis, MD, MSC ,i,j Karen Tu, MD, MS C,k,l,m Jacob A. Udell, MD, MPH,b,c,d,g,n Harindra C. Wijeysundera, MD, PH D, a,b,c,d Dennis T. Ko, MD, MS C
doi : 10.1016/j.jacc.2022.07.026
Volume 80, Issue 14, 4 October 2022, Pages 1330-1342
Recalibrating 10-Year Risk Models Using Population-Based Data: Not Without Caveats∗
Martin Bødtker Mortensen, MD, PHD
doi : 10.1016/j.jacc.2022.08.006
Volume 80, Issue 14, 4 October 2022, Pages 1343-1345
The Athlete’s Heart—Challenges and Controversies: JACC Focus Seminar 4/4
Andre La Gerche, MBBS, PH D, a,b,c Meagan M. Wasfy, MD, MPH, d,e Maria J. Brosnan, MBBS, P HD, b,c Guido Claessen, MD, PHD, f,g Diane Fatkin, MD,h,i,j Hein Heidbuchel, MD, P HD, k,l Aaron L. Baggish, MD, d,e Jason C. Kovacic, MBBS, PHD
doi : 10.1016/j.jacc.2022.07.014
Volume 80, Issue 14, 4 October 2022, Pages 1346-1362
Regular exercise promotes structural, functional, and electrical remodeling of the heart, often referred to as the “athlete’s heart,� with intense endurance sports being associated with the greatest degree of cardiac remodeling.
Myocarditis Following SARS-CoV2 mRNA Vaccination Against COVID-19: Facts and Open Questions
Stephane Heymans, MD, P HD, a,b Dana Dawson, DM, D.P HIL,c Valentin Fuster, MD, PHD, d,e Marco Metra, MD, PH D, f Carlo Gabriele Tocchetti, MD, PH D
doi : 10.1016/j.jacc.2022.08.003
Volume 80, Issue 14, 4 October 2022, Pages 1363-1365
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee
doi : 10.1016/j.jacc.2022.07.006
Volume 80, Issue 14, 4 October 2022, Pages 1366-1418
